|
1
|
Safe S, Papineni S and Chintharlapalli S:
Cancer chemotherapy with indole-3-carbinol, bis(3′-indolyl)methane
and synthetic analogs. Cancer Lett. 269:326–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chinnakannu K, Chen D, Li Y, Wang Z, Dou
QP, Reddy GP and Sarkar FH: Cell cycle-dependent effects of
3,3′-diindolyl-methane on proliferation and apoptosis of prostate
cancer cells. J Cell Physiol. 219:94–99. 2009. View Article : Google Scholar
|
|
3
|
Jin Y, Zou X and Feng X:
3,3′-Diindolylmethane negatively regulates Cdc25A and induces a
G2/M arrest by modulation of microRNA 21 in human breast cancer
cells. Anticancer Drugs. 21:814–822. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang YQ, Chen C, Chen Z, Xu Y, Wang Y,
Xiao BK, Chen SM and Tao ZZ: Indole-3-carbinol inhibits cell
proliferation and induces apoptosis in Hep-2 laryngeal cancer
cells. Oncol Rep. 30:227–233. 2013.PubMed/NCBI
|
|
5
|
Ahmad A, Kong D, Wang Z, Sarkar SH,
Banerjee S and Sarkar FH: Down-regulation of uPA and uPAR by
3,3′-diin-dolylmethane contributes to the inhibition of cell growth
and migration of breast cancer cells. J Cell Biochem. 108:916–925.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim EJ, Shin M, Park H, Hong JE, Shin HK,
Kim J, Kwon DY and Park JH: Oral administration of
3,3′-diindolylmethane inhibits lung metastasis of 4T1 murine
mammary carcinoma cells in BALB/c mice. J Nutr. 139:2373–2379.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ali S, Banerjee S, Ahmad A, El-Rayes BF,
Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is
potentiated by 3,3′-diindolylmethane in vitro and in vivo using an
orthotopic model of pancreatic cancer. Mol Cancer Ther.
7:1708–1719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rahman KMW, Banerjee S, Ali S, Ahmad A,
Wang Z, Kong D and Sakr WA: 3,3′-Diindolylmethane enhances
taxotere-induced apoptosis in hormone-refractory prostate cancer
cells through survivin down-regulation. Cancer Res. 69:4468–4475.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith S, Sepkovic D, Bradlow HL and Auborn
KJ: 3,3′-Diindolyl-methane and genistein decrease the adverse
effects of estrogen in LNCaP and PC-3 prostate cancer cells. J
Nutr. 138:2379–2385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vivar OI, Lin CL, Firestone GL and
Bjeldanes LF: 3,3′-Diindolyl-methane induces a G1 arrest
in human prostate cancer cells irrespective of androgen receptor
and p53 status. Biochem Pharmacol. 78:469–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu EL, Chen N, Westbrook A, Wang F, Zhang
R, Taylor RT and Hankinson O: CXCR4 and CXCL12 down-regulation: A
novel mechanism for the chemoprotection of 3,3′-diindolylmethane
for breast and ovarian cancers. Cancer Lett. 265:113–123. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajoria S, Suriano R, George A, Shanmugam
A, Schantz SP, Geliebter J and Tiwari RK: Estrogen induced
metastatic modulators MMP-2 and MMP-9 are targets of
3,3′-diindolylmethane in thyroid cancer. PLoS One. 6:e158792011.
View Article : Google Scholar
|
|
14
|
Chen C, Chen SM, Xu B, Chen Z, Wang F, Ren
J, Xu Y, Wang Y, Xiao BK and Tao ZZ: In vivo and in vitro study on
the role of 3,3′-diindolylmethane in treatment and prevention of
nasopharyngeal carcinoma. Carcinogenesis. 34:1815–1821. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manach C, Williamson G, Morand C, Scalbert
A and Rémésy C: Bioavailability and bioefficacy of polyphenols in
humans. I. Review of 97 bioavailability studies. Am J Clin Nutr.
81(Suppl 1): 230S–242S. 2005.PubMed/NCBI
|
|
16
|
Howells LM, Moiseeva EP, Neal CP, Foreman
BE, Andreadi CK, Sun YY, Hudson EA and Manson MM: Predicting the
physiological relevance of in vitro cancer preventive activities of
phytochemicals. Acta Pharmacol Sin. 28:1274–1304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cho HJ, Park SY, Kim EJ, Kim JK and Park
JH: 3,3′-Diindolyl-methane inhibits prostate cancer development in
the transgenic adenocarcinoma mouse prostate model. Mol Carcinog.
50:100–112. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heath EI, Heilbrun LK, Li J, Vaishampayan
U, Harper F, Pemberton P and Sarkar FH: A phase I dose-escalation
study of oral BR-DIM (BioResponse 3,3′- Diindolylmethane) in
castrate-resistant, non-metastatic prostate cancer. Am J Transl
Res. 2:402–411. 2010.PubMed/NCBI
|
|
19
|
Moiseeva EP, Almeida GM, Jones GDD and
Manson MM: Extended treatment with physiologic concentrations of
dietary phytochemicals results in altered gene expression, reduced
growth, and apoptosis of cancer cells. Mol Cancer Ther.
6:3071–3079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koon HK, Chan PS, Wong RNS, Wu ZG, Lung
ML, Chang CK and Mak NK: Targeted inhibition of the EGFR pathways
enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated
nasopharyngeal carcinoma cells. J Cell Biochem. 108:1356–1363.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Horikawa T, Yoshizaki T, Kondo S, Furukawa
M, Kaizaki Y and Pagano JS: Epstein-Barr Virus latent membrane
protein 1 induces Snail and epithelial-mesenchymal transition in
metastatic nasopharyngeal carcinoma. Br J Cancer. 104:1160–1167.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qu C, Liang Z, Huang J, Zhao R, Su C, Wang
S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the
radioresistance of human nasopharyngeal carcinoma by directly
targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong VC, Chen H, Ko JM, Chan KW, Chan YP,
Law S, Chua D, Kwong DL, Lung HL, Srivastava G, et al: Tumor
suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell
invasion and epithelial-mesenchymal transition (EMT)-associated
phenotype. Int J Cancer. 130:83–95. 2012. View Article : Google Scholar
|
|
24
|
Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin
J, Feng GK and Zhu XF: Dual phosphoinositide 3-kinase/mammalian
target of rapamycin inhibitor NVP-BEZ235 has a therapeutic
potential and sensitizes cisplatin in nasopharyngeal carcinoma.
PLoS. 8:e598792013. View Article : Google Scholar
|
|
25
|
Xie YQ, Wu XB and Tang SQ: Curcumin
treatment alters ERK-1/2 signaling in vitro and inhibits
nasopharyngeal carcinoma proliferation in mouse xenografts. Int J
Clin Exp Med. 7:108–114. 2014.PubMed/NCBI
|
|
26
|
Chen LC, Liu HP, Li HP, Hsueh C, Yu JS,
Liang CL and Chang YS: Thymidine phosphorylase mRNA stability and
protein levels are increased through ERK-mediated cytoplasmic
accumulation of hnRNP K in nasopharyngeal carcinoma cells.
Oncogene. 28:1904–1915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peng C, Liu HY, Zhou M, Zhang LM, Li XL,
Shen SR and Li GY: BRD7 suppresses the growth of nasopharyngeal
carcinoma cells (HNE1) through negatively regulating beta-catenin
and ERK pathways. Mol Cell Biochem. 303:141–149. 2007. View Article : Google Scholar : PubMed/NCBI
|
